People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tyme Technologies, Inc. | — | Pharmaceuticals | Series B | $20.0M | $680.1M | 2020 |
Douglas Michels at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Michels on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tommy G. Thompson | 1 | 7 |
| STEVE HOFFMAN | 1 | 3 |
| Timothy C. Tyson | 1 | 3 |
| Barbara Galani | 1 | 1 |
| Paul H. Sturman | 1 | 1 |
| Ben R. Taylor | 1 | 1 |
| Giuseppe R. Del Priore | 1 | 1 |
| Jonathan R. Eckard | 1 | 1 |
| David R. Carberry | 1 | 1 |
| Gerald H. Sokol | 1 | 1 |
| Donald DeGolyer | 1 | 1 |
| Michele R. Korfin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.